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Abstract
Background: The potential interest of antifungal treatment of non-immunocompromized patients with sepsis,
extra-digestive Candida colonization and multiple organ failure is unknown. It represents three-quarters of
antifungals prescribed in Intensive Care Units. It may allow early treatment of invasive fungal infection in the
incubation phase but expose patients to unnecessary antifungal treatments with subsequent cost and fungal
selection pressure. As early diagnostic tests for invasive candidiasis are still considered to be insufficient, the
potential interest in this strategy needs to be demonstrated.
Methods: This prospective multicenter, double blind, randomized-controlled trial is conducted in 23 French
Intensive Care Units. All adult patients, mechanically ventilated for more than four days with sepsis of unknown
origin and with at least one extradigestive fungal colonization site and multiple organ failure are eligible for
randomization. Patients with proven invasive candidiasis are not included. After a complete mycological screening,
patients are allocated to receive micafungin 100 mg intravenously once a day or placebo for 14 days. We plan to
enroll 260 patients. The main objective is to demonstrate that micafungin increases survival of patients without
invasive candidiasis at day 28 as compared to placebo. Other outcomes include day 28 and 90 survival and organ
failure evolution. Additionally, pharmacokinetics of micafungin in enrolled patients will be measured and evolution
of fungal biomarkers and susceptibility profiles of infecting fungi will also be followed.
Discussion: This study will help to provide guidelines for treating non-immunocompromized patients with fungal
colonization multiple organ failure and sepsis of unknown origin.
Trial registration: Clinicaltrials.gov number NCT01773876
Keywords: Colonization, Nosocomial sepsis, Candidemia, Invasive candidiasis, Micafungin
Background
Candida, one of the most frequently recovered pathogens
in patients with hospital acquired bloodstream infections
[1,2], is associated with a large increase in mortality [3-5].
Candida accounts for up to 17% of all ICU-acquired in-
fections [6] and multiple-site Candida colonization is
found in approximately half of medical and surgical pa-
tients [7,8]. Major risk factors for Candida colonization
include length of ICU stay, use of parenteral nutrition,
broad-spectrum and long-term antibiotics, central lines,
and abdominal surgery. Importantly, a continuum exists
between Candida colonization and candidemia [9]. Thus,
a colonization index (number of colonized sites/number
of sampled sites) > 0.5 is associated with an increased risk
of candidemia with recovery of the same Candida species
or genotypes in the colonized sites and bloodstream [8].
Studies done to develop a Candida score showed that
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factors associated with candidemia were surgery, multiple-
site Candida colonization, severe sepsis, and parenteral
nutrition [10]. Thus, Candida colonization, although not
unique, is a reliable independent risk factor for candidemia
[11-13]. Therefore, early systemic antifungal therapy
(SAT) may deserve consideration in ICU patients.
Delays in initiating appropriate treatment have been
associated with increased mortality in patients with
bloodstream infections [3]. The same findings have been
reported in patients with candidemia [14-17]. However,
the performance of available diagnostic tools for diagnos-
ing candidemia remains limited [11,12,18,19]. Therefore,
in an attempt to decrease Candida-related mortality,
an increasing number of ICU patients without docu-
mented candidemia are receiving empirical SAT [20,21].
Over the last 15 years, several studies have evaluated
the potential benefits from SAT in ICU patients overall
[22-27] and in the subset of ICU patients having risk
factors for candidemia or sepsis of unknown origin
[28,29]. Prophylactic SAT has been suggested for the
sickest surgical ICU patients, most notably those with
peritonitis [30]. However, results from a recently pub-
lished trial in medical-surgical ICU patients do not
support routine SAT in patients with nonresolving sep-
sis but no Candida colonization [29]. No study has
been conducted in the same patients with multiple-site
Candida colonization. The appropriate modalities of
use [31] of SAT and the potential benefits ascribable
to SAT in ICU patients with sepsis and Candida
colonization have not been reported. We therefore set
up the EMPIRICUS trial to answer this question.
Methods/Design
EMPIRICUS is a prospective, multicenter, randomized,
double-blind, and parallel group study comparing the inter-
est of 14-day empirical micafungin treatment (Mycamine™
Astellas Pharma, Levallois Perret, France 100 mg IV once a
day) with placebo, regarding survival without invasive can-
didiasis during 28 days in adult patients with suspected in-
vasive candidiasis (EudraCT 2011-005451-14).
Ethics
The study involves 23 ICUs in French hospitals (mainly
university affiliated) and was approved by the local Inde-
pendent Ethic Committee (Comité de Protection des
Personnes CPP Sud Est V) on 7 December 2011 and the
French Health Authorities (AFSSAPS) on 2 December
2011. The University Hospital of Grenoble is the spon-
sor of the trial.
Each patient will have given written informed consent
concerning the study design and outcomes. If the infor-
mation could not be delivered to the patient, it will be
delivered to his/her relatives.
The study is divided in two consecutive periods for
each patient:
 the 14-day treatment period starting the day after
the inclusion visit (D0);
 the post-treatment evaluation period from D15 to
D90 with an evaluation visit at D21, D28 (end-of-
study visit, EOS) and collection of information about
long-term survival at three months (during a con-
sultation or by phone contact).
In case of discharge from ICU before having com-
pleted the 14-day study treatment period, the patient
must receive or have received the study treatment dur-
ing at least seven days.
All patients who received at least one dose of study
treatment will be included in the intent-to-treat analysis.
Aims
The EMPIRICUS study primarily aims to evaluate the
efficacy of early empirical treatment with micafungin in
adult ICU patient with suspected invasive candidiasis in
increasing proven-invasive-candidiasis-free-survival at
day 28.
Secondary objectives are:
 To evaluate the impact of empirical micafungin
treatment of patients with possible invasive
candidiasis on:
All-cause mortality at D28 (EOS) and D90
(three months post-randomization)
Antifungal-free survival at D28
Organ failure evolution throughout the trial
Mechanical ventilation use during the trial
Colonization index evolution throughout the trial
Serum biomarkers ((1–3)-β-D-glucan level,
mannan antigenemia, anti-mannan antibodies,
blood Candida PCR) evolution throughout
the trial
Incidence of ventilator-associated bacterial
pneumonia
Pharmacokinetic/pharmacodynamic (PK/PD)
profile of micafungin in ICU ventilated patients
with sepsis
 To characterize the profile of tolerance of
micafungin in ICU ventilated patients with sepsis
Participants
Patients are eligible for inclusion if they fulfill all the in-
clusion and non inclusion criteria described in Table 1.
Patients are screened by the clinical research monitors
and investigators in each center on a daily basis accord-
ing to patient status and known yeast colonization.
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If an invasive fungal infection is evidenced by the
laboratory tests of baseline samples from a patient
who has been included, they are withdrawn from the
study and treated according to current IDSA guide-
lines [31].
Proven Candida IFIs are defined according to the modi-
fied criteria of EORTC/MSG Fungal Infections Consensus
Group 2008:
 Histopathologic, cytopathologic, or direct
microscopic examination of a specimen obtained by
biopsy or needle aspiration (other than mucous
membranes) from a normally sterile site showing
yeast cells, true hyphae or pseudohyphae, or
 Recovery of Candida by culture of a sample
obtained by a sterile procedure (including a freshly
placed (< 24 hours previously) drain) from a
normally sterile site showing a clinical or
radiological abnormality consistent with an
infectious disease process, or
 Blood culture that yields Candida
Study management
The Steering Committee is composed of three intensi-
vists (JFT, EA, MW), two mycologists (MC and JPG)
and two pharmacists (ES, VJ). JFT, EA, MW are in
charge of questions to the investigators, of checking the
clinical consistencies of the outcome variables, and of
asking for complementary clinical data for classifying pa-
tients and events. They will validate before database
lock, blindly to the study group, all the outcome vari-
ables. Definite validation will require consensus. MC and
JPG are in charge of the relationship with mycologists
between centers, processes and analyses. VJ is respon-
sible for pharmacokinetics dosage and models. ES is re-
sponsible for adverse event collection and declaration.
Table 1 Inclusion and non inclusion criteria
Main inclusion criteria • Age≥ 18 years
• Hospitalization in ICU≥ five days (120 hours) before randomization
• Suspected but unproven candidiasis:
Systemic inflammatory response syndrome (SIRS) manifested by two signs among four
(body temperature < 36°C or > 38°C; heart rate > 90/minute; respiratory rate > 20/minute or
PaCO2 < 32 mmHg; white blood cells > 12,000/mm
3, < 4,000/mm3 or > 10% of circulating
immature forms)
Mechanical ventilation ≥ four days
Presence of a central vein catheter and/or an arterial line
Use of broad spectrum antibacterial agents≥ four days during the last seven days
• Organ failure is defined as a sepsis-related organ failure assessment (SOFA) score≥ 3
•At least one extra-digestive site of Candida sp. colonization (urine, mouth, throat, upper
and lower respiratory system, skin folds and drains and postoperative aspiration, and so on);
positive samples from rectal swab and/or stool culture are not taken into account although
they are collected at randomization visit
• No evidence of bacterial infections that explain the symptoms
• No evidence of invasive fungal infections (positive blood culture, direct examination or
positive culture from surgery site, deep biopsy with mycosis) or mould infection according
to the criteria of the ‘fungal infection cooperative group of EORTC’ [De Pauw 2008 ]
Main non inclusion criteria • Proven invasive infection (positive blood culture with yeast, positive culture from surgery
site (only samples taken during surgery or by percutaneous puncture), deep biopsy with
mycosis) including aspergillosis requiring antifungal treatment at the time of randomization
• Patients status considered by the investigator to inevitably leading to death or to withdrawal
of life support within 48 hours
• Antifungal treatment with an echinocandin > one day or with any other antifungal
agent > 72 hours the week preceding the inclusion
• Allergy, hypersensitivity or known intolerance to antifungal echinocandins or to any excipient
composing the study drug
• Neutropenia (neutrophil count < 500/mm3)
• Previous marrow or organ transplantation
• Recent chemotherapy (since less than six months)
• Ongoing systemic immunosuppressant agents therapy, other than corticosteroids at doses
< 2 mg/kg/day of prednisolone or equivalent
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The Data Safety Monitoring Board (DSMB), composed
of five external experts, regularly monitors the safety of
the trial and will inform the Steering Committee in case
of events putting into question the clinical and biological
safety of the study drugs (occurrence of SAEs, publica-
tion of results of a similar trial, and so on). When the in-
clusion of the 50th and 150th patients is achieved, the
DSMB will be provided with two statistical analyses of
the SAEs reported with micafungin, liver function tests
(bilirubin, ALT, AST, alkaline phosphatases, prothrombin
time), venous thromboembolic and cardiovascular condi-
tions, invasive candidiasis, deaths and study withdrawals.
The Adjudication Committee composed of the investiga-
tors and a mycologist will also adjudicate all suspected or
proven candidiasis cases before the unblinding of study data.
The Adjudication Committee will review all the data
from dying patients before day 28 and of patients for
whom an antifungal treatment will be started.
Micafungin is provided by Astellas Laboratories to the
Albert Michallon Hospital University of Grenoble, re-
search pharmacist. Lc2 (Lentilly, France) is the CRO re-
sponsible for the preparation and labeling of batches
and for providing each site with the necessary number
of therapeutic units throughout the study progress.
FOVEA (Rueil-Malmaison, France) is in charge of the
monitoring of each patient file and Delta Consultant
(Eybens, France), which has created the e-CRF, generates
the queries, prepare a statistical analysis plan for safety
interim analyses and the final primary analysis (primary
end-point and secondary clinical end-points). OUTCO-
MEREA (Paris, France) has created the randomization
list and will perform the final statistical analysis.
Randomization and study treatments
Eligible patients are randomly assigned, in a 1:1 ratio, to re-
ceive micafungin 100 mg/day (Mycamine®, Astellas Pharma,
Levallois Perret, France) or matched placebo (100 ml NaCl
0.9%), administered intravenously as a one-hour perfusion.
Randomization is stratified by centers. They also are ran-
domized between two groups: A and B. Randomization is
performed via the website https://empiricus.calystene.fr.
After having completed the ‘randomization’ web page, the
investigator receives the patient’s number. The pharma-
ceutical order including the patient’s number is transmit-
ted to the pharmacist who prepares treatment (micafungin
or placebo) according to the randomization list.
Reconstitution of bags is performed either by the
pharmacist (under extractor hood) or by an external nurse,
both in unblinded conditions. Micafungin and placebo so-
lutions provided to the site for infusion to the patient are
indistinguishable to ensure that the medication blinding is
maintained for both patient and investigator throughout
the study. Study drug administration starts immediately
after the inclusion visit and lasts 14 days.
Time zero is defined by randomization. Pharmaceutical
reconstitution and biological sampling are immediately
performed and the study treatment is started just after.
A form is filled by the pharmacist for each prepar-
ation. The nurse in charge of the patient fills and signs a
nurse form with the times of start and end of infusions.
Empty vials and packs are checked by the research
pharmacist before destruction for the evaluation of com-
pliance for all the patients.
If the existence of an invasive candidiasis at inclusion is
evidenced by the analysis of baseline samples (results of
the exams performed before or during the first 48 hours
of the study treatment), the study treatment will be
stopped and the patient will receive antifungal treatment
usually prescribed in the investigational site, but blinding
is not broken and the patient remains in the intent-to-
treat analysis. During the treatment period, if an invasive
candidiasis is evidenced, the study treatment is stopped;
the antifungal treatment is started according to the deci-
sion of the investigators. Investigators can use micafungin,
or alternatively, another antifungal drug according to
current guidelines [31]. In this latter case, the patient stops
taking the study drug but remains in the study and the in-
vestigator performs the end-of-treatment assessments im-
mediately and the end-of-study visit 28 days later.
Data collection
An e-CRF is used for each patient to collect the data.
Assessments are made at the screening period, inclusion
(D0) and on days 1 to 7, 9, 11, 14, 21, 28 and 90 (phone
contact). Assessments include sepsis-related organ fail-
ure assessment (SOFA), monitoring (catheter, tubes and
drains, mechanical ventilation procedures, inotropes),
candidiasis evaluation (signs, imaging, mycological tests),
laboratory tests (hematology, biochemistry, urinalysis,
pregnancy test at inclusion only), microbiology (blood
cultures, mycology). Biomarker dosages are performed
blindly to the study group by the mycology and pharma-
cokinetic investigators and included in separated files.
The results are not given to the clinical investigators.
The existence of molecular markers of resistance (FKS1
and any other) is investigated in case of positive blood
culture. Adverse events, compliance and concomitant
treatments are collected at each visit.
In cases of invasive candidiasis, treatment used and
complications detected by the attending physicians are
collected. At D90, information about patient survival
is collected.
Laboratory tests and pharmacokinetic sampling
Table 2 summarizes all the laboratory tests performed
throughout the study.
Microbiological analyses of blood cultures and colonization
sites are performed by local laboratories according to
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standardized procedures for in vitro identification of micro-
organisms. Briefly, specimens for mycological analyses are
cultured on Sabouraud-chloramphenicol or any chromo-
genic medium, according to the usual procedures of the local
mycology laboratory, and incubated at 37°C for at least five
days. Species identification is performed using carbohydrate
assimilation profile or mass spectrometry where available.
The objectives of local mycological analyses are to check for
the presence of at least one extra-digestive site of Candida
sp. colonization before inclusion (inclusion criteria). Blood
cultures and sampling of any normally sterile site are imme-
diately collected in case of a new or severe sepsis or a septic
shock. Furthermore, blood cultures are systematically per-
formed on days 3, 7, 14 and 28. In case of positive culture
for Candida from a deep site or blood, the specimen is
stored in Sabouraud broth at 4°C or in standard freezing
medium with glycerol at −80°C before being sent to the
Grenoble University Hospital at site closure. The centralized
analyses performed on these invasive isolates will include the
identification of molecular markers associated with antifun-
gal resistance. Samples for identification of molecular
markers of resistance are collected on dry tubes, centrifuged,
decanted in one aliquot of about 2 to 2.5 ml of serum and
stored in a serum bank at −20°C.
Dosages of biomarkers (blood PCR Candida, (1–3)-β-
D-glucan level, mannan antigenemia, anti-mannan anti-
bodies) are performed in the centralized laboratories of
Parasitology-Mycology of Rennes and Grenoble University
Hospitals. Blood samples for mycology and PK/PD as well
as isolated strains of proven or treated Candida infections
are transferred from the sites to Grenoble each month.
The biobank (serum aliquots and strains) is equally dis-
patched between Grenoble and Rennes laboratories during
the study progress.
Measurements of PK parameters (distribution volume,
clearances, AUC, Cmax, Cmin, AUC/MIC, Cmax/MIC)
are performed centrally in the Pharmacology Department
of Georges Pompidou University Hospital, Paris Descartes
University (Dr V Jullien). Five blood samples for PK ana-
lysis are planned for each patient, three after the first study
drug perfusion and two after the second, according to the
following sampling scheme: at the end of first perfusion;
15 to 30 minutes after; immediately before the second per-
fusion and between 1 to 3 hours and 8 to 12 hours later.
Table 2 Laboratory tests
Laboratory test Sampling days Measured parameters
Hematology (3 ml blood sampling, local laboratory) D0, every day of first week
of treatment, D9, D11, D14
(EOT), D21, D28 (EOS)
Hb, hematocrit, WBC, RBC, platelets
Biochemistry (3 ml blood sampling, local laboratory) D0, every day of first week
of treatment, D9, D11, D14
(EOT), D21, D28 (EOS)
Na, K, Ca, glucose, AST, ALT, alkaline
phosphatases, total bilirubin, prothrombin
time, albumin, serum creatinine
Procalcitonin (local lab) D0, D3, D7, D14 (EOT)
Urinalysis (local lab) D0, D1, D7, D14 (EOT) Proteins, creatinine
Blood culture (10 ml blood sampling) D0, D3, D7, D14 (EOT),
D28 (EOS)
Analyses in the local laboratory, completed
with further centralized analyses in case of
positive results
Mycological follow-up of colonization D0 Culture of specimens of mouth, throat, upper
and lower respiratory tract, skin folds, urine
and lower gastro-intestinal tract (rectal swab
and feces), and if necessary drains, catheters
and postoperative aspiration. In case of positive
culture, an in vitro sensitivity study (E-test) to
pre-defined antifungal agents is performed at
inclusion on isolates
Analyses in the local laboratory, completed with
further centralized analyses in case of positive results
Centralized microbiological analyses of blood samples
and positive blood cultures (Mycology-Parasitology
Departments of Grenoble and Rennes University Hospitals)
D0, D3, D7, D14, D28 Biomarkers: blood PCR Candida analysis and
(1–3)-β-D-glucan level, mannan antigen, anti-mannan
antibodies tests if patient exhibits symptoms of
invasive candidiasis
In case of positive blood culture or deep sites:
search for molecular resistance markers (biobank)
PK sampling (5 ml blood sampling) D0, D1 Three samples following first study drug intake and
two following the second intake. Sampling times
specific to groups A and B
EOT: end-of-treatment.
EOS: end-of-study (day 28).
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Maintenance of blood sample integrity
For PK studies, samples of 5 ml of whole blood are taken,
placed in dry heparin tubes and centrifuged within one
hour after collection. Following the separation of plasma
into two aliquots in polypropylene tubes, aliquots are fro-
zen at −80°C and sent on dry ice to the laboratory once a
month. Micafungin plasma concentration will be deter-
mined using an ultra-high pressure liquid chromatographic
with fluorimetric detection method that was validated
according to European guidelines for the validation of bioa-
nalytical methods (Guideline EMEA/CHMP/EWP/192217/
2009). Blood samples used for blood cultures are collected
with a fungal specific tube if possible, or with a couple of
aerobic/anaerobic bottles.
Sample size and power
Hypotheses for the sample size calculation were:
 The mortality of patients fulfilling the selection
criteria has been estimated between 30% and 37%
(OUTCOMEREA French database [32,33])
 The candidemia related mortality in case of early
treatment is 12% whereas it is 35% when the
treatment is delayed (current practice) [17]
 According to Schuster et al. [29], IFIs should be
expected to be diagnosed in 7.1% of patients
receiving antifungal therapy and 20.8% of those
receiving placebo (absolute difference 13.7%)
 Traditional sensitivity diagnostic test (blood cultures,
culture of sterile site) of IFI diagnosis is 60%
Then, in the micafungin group, the actual incidence of
IFIs can be estimated at 11.8% (7.1%/0.6), the candide-
mia related mortality at 1.4% (11.8% x 12%) and overall
events between 31.4% and 38.4%. In the placebo group,
the candidemia related mortality can be estimated at
4.13% (11.8% × 35%), the number of additional IFIs diag-
nosed after randomization at 13.7% [29] and overall
events between 49.4% and 56.4%. This difference of 18%
in the proportions of events between both groups is then
an acceptable hypothesis. A two-sided log-rank test with
an overall sample size of 235 subjects (of which 118 are
in micafungin group and 117 are in placebo group)
achieves 80% power at a 0.0500 significance level to de-
tect a difference of 0.18 between 0.37 and 0.55 - the pro-
portions surviving in groups micafungin and placebo,
respectively [34]. This corresponds to a hazard ratio of
0.6013. These results are based on the assumption that
the hazard rates are proportional. It could be assumed
that 5% of the enrolled population will be included but
not randomized. The absence of follow-up of patients at
day 28 is very improbable (withdrawal of informed con-
sent) and can be assumed to be 5%. A total number of
260 patients (130 in each arm) should then be included.
Statistical and PK analysis
Biostatistics and epidemiology team of OUTCOMEREA is
in charge of statistical analysis of the study data and will
use SAS 9x (SAS, Inc., Cary, NC, USA) and R (R founda-
tion for statistical computing, Vienna, Austria) softwares.
Group comparisons will be performed on an intent-to-
treat basis. Data will be reported as numbers (percentages)
or medians (interquartile ranges: 25th to 75th percentiles).
Continuous variables will be compared using the Wil-
coxon rank sum test and proportion using the Fisher exact
test. Death or proven IFI (primary end-point) will be eval-
uated at end-of-study and analyzed with survival methods
of Kaplan-Meier estimate for each treatment group of full
analysis set (randomized patients). Patients who received
at least one dose of study drug will be kept in the intent-
to-treat analysis even if invasive Candida infection was di-
agnosed during the first 48 hours of randomization.
Secondary efficacy end-point will be evaluated simi-
larly in the intent-to-treat population. The Cox model
will be used if adjustment variables must be taken into
account. Proportional assumption will be assessed using
graphical methods. All the analyses will be stratified by
center. No interim analyses are planned. Missing, un-
used data or outliers will lead to queries. In the cases
where they are confirmed, the data concerning the inde-
pendent variables will be replaced using multiple imput-
ation methods.
According to French legislation, serious unexpected ad-
verse events will be immediately communicated to the
French Health authorities and placed in the Eudravigi-
lance™ database. Safety analyses will be done after 50 and
150 included patients or more upon request of DSMB.
Vital signs, body weight and temperature, clinical exami-
nations and laboratory tests will be described. Adverse
events will be summarized by system after coding. Inci-
dence of patients with at least one AE general or of special
interest, per group, will be calculated and summarized in
tables. The incidence of AEs will be described per group
in tables, according to severity and imputability to study
drug. SAEs will also be summarized in tables and detailed
in a separate section and reported to the Regional Phar-
macovigilance Center. Changes between baseline and end-
of-treatment in vital signs and laboratory tests will be
described for each treatment group.
PK analysis will be performed according to a population
approach (NONMEN software, ICON, Dublin, Ireland).
PK parameters of population (means, inter and intraindivi-
dual variability) will be estimated with overall data. The fol-
lowing covariates will be studied: age, weight, concomitant
medications, proteinemia, albuminemia, prothrombin time,
ALT, AST, nature and volume of intravenous fluids that
were used, evolution of weight between admission to ICU
and day of PK sampling, evolution of proteinemia between
admission to ICU and day of PK sampling. Significance of
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relationship between covariates and PK parameters will be
evaluated with the modification of the objective function
and impact on interindividual variability of PK parameters.
A decrease of at least 3.84 points (α = 5%) in objective
function will be used as significance criteria for the ascend-
ant phase. For the decreasing phase, an increase in object-
ive function of at least 6.63 points (α = 1%) will be
required. The final model will be validated using visual pre-
dictive checks and normalized prediction errors. PK/PD
statistical analyses will be performed by the Pharmacology
Department of Dr V Jullien.
Discussion
Regarding benefits to expect from empirical or preemptive
SAT in critically ill non-immunocompromized patients,
the current literature is inconclusive and trials demon-
strating the efficacy of SAT in colonized patients with un-
resolved sepsis and organ dysfunction are warranted.
Appropriate treatment of proven invasive candidiasis
needs to be started as early as possible. Indeed, random-
ized control trials (RCTs) have demonstrated that SAT is
effective in cases of proven invasive fungal infection, but
these latter represent only 15 to 20% of the SAT pre-
scribed in ICU [12,35]. In high-risk digestive surgery pa-
tients managed in ICUs with high annual incidence of
candidemia (that is, > 1 to 2%), prophylaxis may be effect-
ive. However, regarding the so-called preemptive or em-
pirical therapy, no clear demonstration of efficacy has
been published. One before-after study showed decreased
ICU-acquired candidemia using a colonization index-
based fluconazole therapy, but no survival benefits. A
RCT failed to demonstrate an impact of fluconazole on in-
vasive fungal infection or mortality in critically ill patients
with unresolved sepsis and risk factors for candidemia.
The issue remains uncertain because diagnosis of invasive
fungal infection remains a challenge in ICU. In a one-day
prevalence study, the intensivists declared 17% of nosoco-
mial infections to be due to Candida spp. [36], however,
only 99/14,414 patients developed proven candidemia.
Candida colonization is a frequent event in ICU pa-
tients [12]. The colonization index, validated 20 years ago
in long-term surgical ICU patients, has been largely chal-
lenged. For instance, the colonization index positive pre-
dictive value is less than 9% in the EPCAN study [12].
Furthermore, in medical ICU patients, 39% developed a
colonization index of more than 0.5, while, in the same
period, no invasive fungal infections were diagnosed [7].
New tools such as (1–3)-β-D-glucan levels provide prom-
ising results in ICU population [37,38]. However, (1–3)-β-
D-glucan is not specific of candidiasis, is higher than
80 pg/ml in many ICU patients without invasive candidia-
sis and decreases slowly under effective treatment [39-41].
New antifungal agents are well tolerated and overtreat-
ment might be considered as safe at a patient level.
However, new data from US and Europe clearly demon-
strate that overuse of antifungal drugs contributes to
both the emergence of Candida species that are known
to be less sensitive to antifungal agents, as well as to in-
creased MICs of sensitive Candida species. Recently,
Lortholary et al. reported that azole derivatives and can-
din pre-exposure increases the risk of fungemia due to
species with higher MICs to corresponding antifungal
agents [42]. Pfaller et al. found an increase in rates of
fluconazole-resistant Candida glabrata intermediate or
resistant to candins over time from less than 4% between
2000 and 2002 to more than 12% between 2008 and
2010 [43]. Dannaoui et al. reported 20 episodes of fungal
infections caused by candin-resistant Candida spp. that
were harboring diverse and new resistance mutations.
For 12 patients, initial isolates (low MICs, wild-type FKS
gene) and subsequent isolates (after caspofungin treat-
ment, high MIC, FKS mutation) were genetically identical
[44]. We also recently described a significant relationship
between SAT consumption and MICs of colonizing and
infecting fungi in ICU patients [45]. Obviously, SAT
should be used by applying the same rules as are ap-
plied to other antimicrobial agents and it must be ef-
fective and safe for the patient in question as well as
for future patients.
Likewise, we are looking forward to having improved
diagnostic strategies so to increase sensitivity, specificity
and predictive values of available tools, as well as to re-
duce diagnostic delays.
Until the results from ongoing trials are available, a
demonstration of a clinical benefit of treatment of such
patients is warranted in order to solve uncertainties
around the issue of deciding antifungal treatment in the
ICU setting.
Trial status
The trial is currently recruiting including patients. The
inclusion started the 10 July 2012 and the number of in-
cluded patients is 50. The estimated length of inclusion
time is sixteen months.
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